Antiviral therapy improves post‐hepatectomy survival in patients with hepatitis B virus‐related hepatocellular carcinoma: a prospective‐retrospective study. Issue 2 (21st November 2014)

• Record Type: Journal Article
• Authors: Chong, C. C. N.; Wong, G. L. H.; Wong, V. W. S.; Ip, P. C. T.; Cheung, Y. S.; Wong, J.; Lee, K. F.; Lai, P. B. S.; Chan, H. L. Y.
• Is Part Of: Alimentary pharmacology & therapeutics. Volume 41:Issue 2(2015)
• Page Start: 199
• Page End: 208
• Publication Date: 2014-11-21
• Subjects: Digestive organs -- Diseases -- Treatment -- Periodicals; Digestive organs -- Effect of drugs on -- Periodicals; Gastrointestinal system -- Diseases -- Treatment -- Periodicals; Gastrointestinal system -- Effect of drugs on -- Periodicals; 615.73
• DOI: 10.1111/apt.13034
• Languages: English
• ISSNs: 0269-2813

Abstract

<abstract abstract-type="main" id="apt13034-abs-0001"> <title>Summary</title> <sec id="apt13034-sec-0001" sec-type="section"> <title>Background</title> <p>The effect of antiviral therapy on the post‐hepatectomy long‐term survival in patients with hepatitis B virus (HBV)‐related hepatocellular carcinoma (HCC) remains uncertain.</p> </sec> <sec id="apt13034-sec-0002" sec-type="section"> <title>Aim</title> <p>To evaluate the effect of antiviral therapy on post‐hepatectomy survival and recurrence in patients with HBV‐related HCC.</p> </sec> <sec id="apt13034-sec-0003" sec-type="section"> <title>Methods</title> <p>This was a prospective‐retrospective study of a total of 404 patients who underwent hepatectomy for HBV‐related HCC in a tertiary academic hospital. Data on patient and tumour characteristics, tumour recurrence, treatment for recurrence and survival were compared between antiviral and no antiviral groups.</p> </sec> <sec id="apt13034-sec-0004" sec-type="section"> <title>Results</title> <p>Patient's and tumour characteristics were comparable between the two groups, except a higher proportion of patients with cirrhosis in the antiviral group. With a mean follow‐up time of 52.4 months, antiviral group had a better 5‐year overall survival (66.7% vs. 56.0%, <italic>P = </italic>0.001) while there was no significant difference in the 5‐year disease‐free survival (44.7% vs. 38.1%, <italic>P = </italic>0.166). Use of antiviral therapy was associated with better liver function reserve at the time of recurrence and a greater proportion of patients could receive curative treatment for recurrence (38.5% vs. 24.3%, <italic>P = </italic>0.041). There was no significant different in the hazard ratios of patients who started antiviral therapy before or after operation (<italic>P = </italic>0.054).</p> </sec> <sec id="apt13034-sec-0005" sec-type="section"> <title>Conclusions</title> <p>Use of antiviral therapy improves the long‐term post‐hepatectomy survival in patients with HBV‐related HCC. With a better liver function reserve at the time of recurrence, a greater proportion of patients in antiviral group could receive curative treatment for recurrence.</p> </sec> </abstract>